The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Open accessAbstract
Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional protein which, besides its catalytic activity, also functions as a binding protein and a ligand for a variety of extracellular molecules. It is an integral membrane protein expressed on cells throughout the body, but is also shed from the membrane and circulates as a soluble protein in the plasma. A large number of bioactive molecules can be cleaved by DPP-4 in vitro, but only a few of these have been demonstrated to be physiological substrates. One of these is the incretin hormone, glucagon-like peptide-1 (GLP-1), which plays an important role in the maintenance of normal glucose homeostasis, and DPP-4 has been shown to be the key enzyme regulating its biological activity. This pathway has been targeted pharmacologically through the development of DPP-4 inhibitors, and these are now a successful class of anti-hyperglycaemic agents used to treat type 2 diabetes (T2DM). DPP-4 may additionally influence metabolic control via its proteolytic effect on other regulatory peptides, but it has also been reported to affect insulin sensitivity, potentially mediated through its non-enzymatic interactions with other membrane proteins. Given that altered expression and activity of DPP-4 are associated with increasing body mass index and hyperglycaemia, DPP-4 has been proposed to play a role in linking obesity and the pathogenesis of T2DM by functioning as a local mediator of inflammation and insulin resistance in adipose and hepatic tissue. As well as these broader systemic effects, it has also been suggested that DPP-4 may be able to modulate β-cell function as part of a paracrine system involving GLP-1 produced locally within the pancreatic islets. However, while it is evident that DPP-4 has the potential to influence glycaemic control, its overall significance for the normal physiological regulation of glucose homeostasis in humans and its role in the pathogenesis of metabolic disease remain to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2513 · Cited by 922
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citationZannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Self-citationDipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D. M., Eckardt, K., Kaufman, J. M., Ryden, M., Müller, S., et al. (2011) · Diabetes · doi:10.2337/db10-1707 · Cited by 582
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
ØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 377
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Grandt, D., Schimiczek, M., Beglinger, C., Layer, P., Goebell, H., Eysselein, V. E., & Reeve, J. R. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90204-6 · Cited by 364
Insulin Secretion Depends on Intra-islet Glucagon Signaling
Svendsen, B., Larsen, O., Gabe, M. B. N., Christiansen, C. B., Rosenkilde, M. M., Drucker, D. J., & Holst, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.018 · Cited by 355
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Deacon, C. F., Hughes, T. E., & Holst, J. J. (1998) · Diabetes · doi:10.2337/diabetes.47.5.764 · Cited by 321
Self-citationFadini, G. P., Boscaro, E., Albiero, M., Menegazzo, L., Frison, V., de Kreutzenberg, S., Agostini, C., Tiengo, A., & Avogaro, A. (2010) · Diabetes Care · doi:10.2337/dc10-0187 · Cited by 318
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Zaruba, M.-M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R., Fischer, R., Krieg, L., Hirsch, E., Huber, B., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.013 · Cited by 301
Deacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Self-citationGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299
Self-citationHepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Ghorpade, D. S., Ozcan, L., Zheng, Z., Nicoloro, S. M., Shen, Y., Chen, E., Blüher, M., Czech, M. P., & Tabas, I. (2018) · Nature · doi:10.1038/nature26138 · Cited by 292
Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects
Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., & Habener, J. F. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.270 · Cited by 289
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Self-citationEffects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285
Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H. S., & Demuth, H.-U. (1998) · Diabetes · doi:10.2337/diab.47.8.1253 · Cited by 267
A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets
Marchetti, P., Lupi, R., Bugliani, M., Kirkpatrick, C. L., Sebastiani, G., Grieco, F. A., Del Guerra, S., D’Aleo, V., Piro, S., Marselli, L., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2716-9 · Cited by 259
Rouillé, Y., Martin, S., & Steiner, D. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26488 · Cited by 245
The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice
Chambers, A. P., Sorrell, J. E., Haller, A., Roelofs, K., Hutch, C. R., Kim, K.-S., Gutierrez-Aguilar, R., Li, B., Drucker, D. J., D’Alessio, D. A., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.02.008 · Cited by 241
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
Ohnuma, K., Dang, N. H., & Morimoto, C. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.010 · Cited by 238
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides
Zhu, L., Tamvakopoulos, C., Xie, D., Dragovic, J., Shen, X., Fenyk-Melody, J. E., Schmidt, K., Bagchi, A., Griffin, P. R., Thornberry, N. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212355200 · Cited by 221
Role of caveolin and caveolae in insulin signaling and diabetes
Cohen, A. W., Combs, T. P., Scherer, P. E., & Lisanti, M. P. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00324.2003 · Cited by 220
Adipose Dipeptidyl Peptidase-4 and Obesity
Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W. T., Dietrich, A., Fielding, B. A., Arner, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0496 · Cited by 218
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas
Deacon, C. F., & Lebovitz, H. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12610 · Cited by 213
Self-citationBalkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206 · cited 4×
“Accordingly, several studies have reported a positive correlation between plasma DPP-4 activity and fasting plasma glucose or HbA1c (68, 72), although it should be borne in mind that an association does not necessarily reflect a causative relationship.”
BackgroundInfluentialReimer, M., Holst, J., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 195
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Ahrén, B., Holst, J. J., Mårtensson, H., & Balkan, B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00600-2 · Cited by 193
Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.05.010 · Cited by 192
The dipeptidyl peptidase IV family in cancer and cell biology
Yu, D. M. T., Yao, T., Chowdhury, S., Nadvi, N. A., Osborne, B., Church, W. B., McCaughan, G. W., & Gorrell, M. D. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07526.x · Cited by 183
Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181
Self-citationShioda, T., Kato, H., Ohnishi, Y., Tashiro, K., Ikegawa, M., Nakayama, E. E., Hu, H., Kato, A., Sakai, Y., Liu, H., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6331 · Cited by 179
Whalley, N. M., Pritchard, L. E., Smith, D. M., & White, A. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0094 · Cited by 178
Nie, Y., Nakashima, M., Brubaker, P. L., Li, Q.-L., Perfetti, R., Jansen, E., Zambre, Y., Pipeleers, D., & Friedman, T. C. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7456 · Cited by 170
McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038352 · Cited by 164
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
Baumeier, C., Schlüter, L., Saussenthaler, S., Laeger, T., Rödiger, M., Alaze, S. A., Fritsche, L., Häring, H.-U., Stefan, N., Fritsche, A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.016 · Cited by 159
Deacon, C., Danielsen, P. B., Klarskov, L., Olesen, M., & Holst, J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 155
Self-citationVarin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.001 · Cited by 142
The safety of gliptins : updated data in 2018
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 138
Miyazaki, M. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.707 · Cited by 137
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 135
Yano, T., Liu, Z., Donovan, J., Thomas, M. K., & Habener, J. F. (2007) · Diabetes · doi:10.2337/db07-0291 · Cited by 132
Catalán, V., Gómez‐Ambrosi, J., Rodrı́guez, A., Silva, C., Rotellar, F., Gil, M. J., Cienfuegos, J. A., Salvador, J., & Frühbeck, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03021.x · Cited by 130
Lugari, R., Cas, A. D., Ugolotti, D., Barilli, A. L., Camellini, C., Ganzerla, G. C., Luciani, A., Salerni, B., Mittenperger, F., Nodari, S., et al. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-814222 · Cited by 128
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1
Ohnuma, K., Yamochi, T., Uchiyama, M., Nishibashi, K., Yoshikawa, N., Shimizu, N., Iwata, S., Tanaka, H., Dang, N. H., & Morimoto, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405266101 · Cited by 126
Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121
Aaboe, K., Knop, F. K., Vilsbøll, T., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01167.x · Cited by 115
Self-citationTraub, S., Meier, D. T., Schulze, F., Dror, E., Nordmann, T. M., Goetz, N., Koch, N., Dalmas, É., Stawiski, M., Makshana, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.005 · Cited by 115
SCHÖN, E., Born, I., Demuth, H., Faust, J., Neubert, K., Steinmetzer, T., Barth, A., & ANSORGE, S. (1991) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1991.372.1.305 · Cited by 114
Shah, P., Ardestani, A. D., Dharmadhikari, G., Laue, S., Schumann, D., Kerr-Conte, J. A., Pattou, F. N., Klein, T., & Maedler, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1029 · Cited by 108
Lovshin, J. A., Rajasekeran, H., Lytvyn, Y., Lovblom, L. E., Khan, S., Alemu, R. Z., Locke, A., LAI, V. S., He, H., Hittle, L. R., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0061 · Cited by 107
PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC
Chen, C. H., Stephens, R. L., & Rogers, R. C. (1997) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.1997.d01-26.x · Cited by 103
Gasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 103
He, Y., Serra, D. B., Wang, Y., Campestrini, J., Rivière, G., Deacon, C. F., Holst, J. J., Schwartz, S. L., Nielsen, J. C., & Ligueros‐Saylan, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746070-00003 · Cited by 102
Self-citationPauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 102
Aulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. R. J. (2013) · Diabetes · doi:10.2337/db13-1455 · Cited by 98
Liu, Z., Stanojevic, V., Avadhani, S., Yano, T., & Habener, J. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2181-x · Cited by 95
Hansen, A. M. K., Bödvarsdóttir, T., Nordestgaard, D. N. E., Heller, R. S., Gotfredsen, C. F., Maedler, K., Fels, J. J., Holst, J. J., & Karlsen, A. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2080-1 · Cited by 89
Hepatic DPP4 DNA Methylation Associates With Fatty Liver
Baumeier, C., Saussenthaler, S., Kammel, A., Jähnert, M., Schlüter, L., Hesse, D., Canouil, M., Lobbens, S., Caiazzo, R. J., Raverdy, V., et al. (2016) · Diabetes · doi:10.2337/db15-1716 · Cited by 89
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, C. F. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.011 · Cited by 89
Self-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., MINNION, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M. J., Beale, K., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2008) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 85
Meneilly, G. S., Demuth, H. U., McIntosh, C. H. S., & Pederson, R. A. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00236.x · Cited by 85
Omar, B. A., Liu, L., Yamada, Y., Seino, Y., Marchetti, P., & Åhrén, B. (2014) · Diabetologia · doi:10.1007/s00125-014-3299-4 · Cited by 84
Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
Pratley, R. E., McCall, T., Fleck, P. R., Wilson, C., & Mekki, Q. A. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02484.x · Cited by 79
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 79
Kirino, Y., Sei, M., Kawazoe, K., Minakuchi, K., & Sato, Y. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0158 · Cited by 72
Wideman, R. D., Covey, S. D., Webb, G. C., Drucker, D. J., & Kieffer, T. J. (2007) · Diabetes · doi:10.2337/db07-0563 · Cited by 72
Bugliani, M., Syed, F., de Paula, F. M. M., Omar, B. A., Suleiman, M., Mossuto, S., Grano, F., Cardarelli, F., Boggi, U., Vistoli, F., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.019 · Cited by 69
Raz, I., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Scirica, B. M., Umez-Eronini, A. A., Im, K., Stahre, C., Buskila, A., Iqbal, N., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2546 · Cited by 67
Fadini, G. P., Albiero, M., Menegazzo, L., de Kreutzenberg, S. V., & Avogaro, A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01550.x · Cited by 65
Liu, Z., & Habener, J. (2009) · Diabetologia · doi:10.1007/s00125-009-1384-x · Cited by 63
Lehrke, M., Marx, N., Patel, S. D., Seck, T. L., Crowe, S., Cheng, K., von Eynatten, M., & Johansen, O. E. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.008 · Cited by 63
Pancreatic Safety of Sitagliptin in the TECOS Study
Buse, J. B., Bethel, M. A., Green, J. B., Stevens, S. R., Lokhnygina, Y. V., Aschner, P. J., Grado, C. A. R., Tankova, T. I., Wainstein, J., Josse, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2780 · Cited by 62
McKillop, A. M., Duffy, N. A., Lindsay, J. R., O'Harte, F. P. M., Bell, P. M., & Flatt, P. R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.001 · Cited by 60
Molecular analysis of CD26-mediated signal transduction in T cells
Hühn, J., Ehrlich, S., Fleischer, B., & von Bonin, A. (2000) · Immunology Letters · doi:10.1016/s0165-2478(00)00170-x · Cited by 60
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
Hirshberg, B., Parker, A., Edelberg, H. K., Donovan, M., & Iqbal, N. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2502 · Cited by 55
Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
Liu, Y. ‐., Ford, H. E., Druce, M. R., MINNION, J. S., Field, B. C. T., Shillito, J. C., Baxter, J. E., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.110 · Cited by 53
Schweizer, A., Dejager, S., Foley, J. E., & Kothny (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s16925 · Cited by 52
Nauck, M. A., Kind, J., Köthe, L., Holst, J. J., Deacon, C. F., Broschag, M., He, Y. L., Kjems, L., & Foley, J. E. (2016) · Diabetes · doi:10.2337/db16-0107 · Cited by 52
Self-citationAaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12395 · Cited by 51
Self-citationVora, K. A., Porter, G., Peng, R., Cui, Y., Pryor, K. D., Eiermann, G. J., & Zaller, D. M. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-19 · Cited by 50
Effect of Aging and Diabetes on the Enteroinsular Axis
Korosi, J., McIntosh, C. H. S., Pederson, R. A., Demuth, H., Habener, J. F., Gingerich, R. L., Egan, J. M., Elahi, D., & Meneilly, G. S. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.9.m575 · Cited by 50
Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2594 · Cited by 50
Pala, L., Pezzatini, A., Dicembrini, I., Ciani, S., Gelmini, S., Vannelli, B., Cresci, B., Mannucci, E., & Rotella, C. M. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0195-3 · Cited by 47
Pala, L., Ciani, S., Dicembrini, I., Bardini, G., Cresci, B., Pezzatini, A., Giannini, S., Mannucci, E., & Rotella, C. M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03010.x · Cited by 46
Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells.
Poulsen, M., Hansen, G. H., Dabelsteen, E., Høyer, P. E., Norén, O., & Sjöström, H. (1993) · Journal of Histochemistry & Cytochemistry · doi:10.1177/41.1.8093256 · Cited by 42
Bianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 41
Reduced DPP4 activity improves insulin signaling in primary human adipocytes
Röhrborn, D., Brückner, J., Sell, H., & Eckel, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.019 · Cited by 40
Ahmed, R. H., Huri, H. Z., Muniandy, S., Al-Hamodi, Z. H., Al-absi, B., Alsalahi, A., & Razif, M. F. M. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.03.008 · Cited by 38
Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure
Koyani, C. N., Kolesnik, E., Wölkart, G., Shrestha, N., Scheruebel, S., Trummer, C., Zorn‐Pauly, K., Hammer, A., Lang, P., Reicher, H., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.021 · Cited by 37
Effects of high glucose on caveolin-1 and insulin signaling in 3T3-L1 adipocytes
Palacios-Ortega, S., Varela-Guruceaga, M., Martínez, J. A., de Miguel, C., & Milagro, F. I. (2015) · Adipocyte · doi:10.1080/21623945.2015.1122856 · Cited by 35
Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets
Liu, L., Omar, B. A., Marchetti, P., & Åhrén, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.096 · Cited by 33
Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
Sancho, V., Daniele, G., Lucchesi, D., Lupi, R., Ciccarone, A., Penno, G., Bianchi, C., Dardano, A., Miccoli, R., & Prato, S. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187836 · Cited by 32
Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells
Augstein, P., Naselli, G., Loudovaris, T., Hawthorne, W. J., Campbell, P. T., Bandala‐Sanchez, E., Rogers, K. L., Heinke, P., Thomas, H. E., Kay, T. W. H., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.010 · Cited by 31
Peptide YY does not inhibit glucose-stimulated insulin secretion in humans
Åhrén, B., & Larsson, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340362 · Cited by 29
Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes
Rufinatscha, K., Radlinger, B., Dobner, J., Folie, S., Bon, C., Profanter, E., Ress, C., Salzmann, K., Staudacher, G., Tilg, H., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.071 · Cited by 27
Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
Koyani, C. N., Trummer, C., Shrestha, N., Scheruebel, S., Bourgeois, B. M. R., Plastira, I., Kickmaier, S., Sourij, H., Rainer, P. P., Madl, T., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01622 · Cited by 27
Grondin, G., Hooper, N. M., & LeBel, D. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700407 · Cited by 24
Anz, D., Krüger, S., Haubner, S., Rapp, M., Bourquin, C., & Endres, S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12246 · Cited by 22
Zhang, Y., Wu, M., Htun, W., Dong, E. W., Mauvais‐Jarvis, F., Fonseca, V. A., & Wu, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-08271-9 · Cited by 13
Carr, R. D. (2016) · Diabetic Medicine · doi:10.1111/dme.13066 · Cited by 12
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Kulcsar, K. A., Coleman, C. M., Beck, S. E., & Frieman, M. B. (2019) · JCI Insight · doi:10.1172/jci.insight.131774 · Cited by 373
Diabetes and COVID-19: A systematic review on the current evidences
Abdi, A., Jalilian, M., Sarbarzeh, P. A., & Vlaisavljevic, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108347 · Cited by 270
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Metadata
- Authors
- Deacon, C. F.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-02-15
- Volume
- 10
- Pages
- 80-80
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2914024845
- Cited by
- 428
- References
- 138
- FWCI
- 30.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.